Comentario: Problemas y mercadeo de las estatinas

All statins inhibit hydroxymethylglutaryl Coenzyme A Reductase but each has a different chemical structure that may have individual advantages. Some pharmaceutical companies have minimized side effects and stated that dose has no relation to incidence. To the contrary, dose is related to side effect...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	WHAYNE, Jr,THOMAS F
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2010
Materias:	Hydroxymethylglutaryl-Co A Reductase inhibitors Hypercholesterolemia Muscular diseases
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872010000400018
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872010000400018
record_format	dspace
spelling	oai:scielo:S0034-988720100004000182010-06-30Comentario: Problemas y mercadeo de las estatinasWHAYNE, Jr,THOMAS F Hydroxymethylglutaryl-Co A Reductase inhibitors Hypercholesterolemia Muscular diseases All statins inhibit hydroxymethylglutaryl Coenzyme A Reductase but each has a different chemical structure that may have individual advantages. Some pharmaceutical companies have minimized side effects and stated that dose has no relation to incidence. To the contrary, dose is related to side effects with all statins. Myopathy occurs in up to 10.5% of patients taking a high dose. There is an attempt to sell statins that have lost patent protection over-the-counter. However, evidence supports medical supervision as offering greatest patient safety. Concerns were raised about ezetimibe after the initial ENHANCE (effcacy) and SEAS (cancer risk) study but these concerns appear to have been answered. Fenofbrate can be used with a statin but gemfbrozil is contraindicated. Coenzyme Q-10 possibly helps to mitigate the risk of myopathy with a statin but evidence is not universally accepted. JUPITER represented a valid outcomes study but made a claim that rosuvastatin has special value in risk management because of decreased high sensitivity C-Reactive Protein. This actually occurs with any statin, a decrease also enhanced by ezetimibe. Statins have benefted the lives of our patients but, as with any treatment, the physician needs to look critically at all the problems and claims made.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.138 n.4 20102010-04-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872010000400018es10.4067/S0034-98872010000400018
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Hydroxymethylglutaryl-Co A Reductase inhibitors Hypercholesterolemia Muscular diseases
spellingShingle	Hydroxymethylglutaryl-Co A Reductase inhibitors Hypercholesterolemia Muscular diseases WHAYNE, Jr,THOMAS F Comentario: Problemas y mercadeo de las estatinas
description	All statins inhibit hydroxymethylglutaryl Coenzyme A Reductase but each has a different chemical structure that may have individual advantages. Some pharmaceutical companies have minimized side effects and stated that dose has no relation to incidence. To the contrary, dose is related to side effects with all statins. Myopathy occurs in up to 10.5% of patients taking a high dose. There is an attempt to sell statins that have lost patent protection over-the-counter. However, evidence supports medical supervision as offering greatest patient safety. Concerns were raised about ezetimibe after the initial ENHANCE (effcacy) and SEAS (cancer risk) study but these concerns appear to have been answered. Fenofbrate can be used with a statin but gemfbrozil is contraindicated. Coenzyme Q-10 possibly helps to mitigate the risk of myopathy with a statin but evidence is not universally accepted. JUPITER represented a valid outcomes study but made a claim that rosuvastatin has special value in risk management because of decreased high sensitivity C-Reactive Protein. This actually occurs with any statin, a decrease also enhanced by ezetimibe. Statins have benefted the lives of our patients but, as with any treatment, the physician needs to look critically at all the problems and claims made.
author	WHAYNE, Jr,THOMAS F
author_facet	WHAYNE, Jr,THOMAS F
author_sort	WHAYNE, Jr,THOMAS F
title	Comentario: Problemas y mercadeo de las estatinas
title_short	Comentario: Problemas y mercadeo de las estatinas
title_full	Comentario: Problemas y mercadeo de las estatinas
title_fullStr	Comentario: Problemas y mercadeo de las estatinas
title_full_unstemmed	Comentario: Problemas y mercadeo de las estatinas
title_sort	comentario: problemas y mercadeo de las estatinas
publisher	Sociedad Médica de Santiago
publishDate	2010
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872010000400018
work_keys_str_mv	AT whaynejrthomasf comentarioproblemasymercadeodelasestatinas
_version_	1718436501832859648

Comentario: Problemas y mercadeo de las estatinas

Ejemplares similares